Free Access
Med Sci (Paris)
Volume 19, Number 8-9, Août-Septembre 2003
Page(s) 819 - 825
Section M/S Revues
Published online 15 August 2003
  1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570–81. [Google Scholar]
  2. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol 2002; 90: 55i–61i. [Google Scholar]
  3. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409–35. [Google Scholar]
  4. Barbier O, Torra IP, Duguay Y, et al. Pleiotropic actions of peroxisome proliferatoractivated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717–26. [Google Scholar]
  5. Vu-Dac N, Gervois P, Jakel H, et al. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to PPAR alpha activators. J Biol Chem 2003; 278: 17982–5. [Google Scholar]
  6. Chinetti G, Gbaguidi FG, Griglio S, et al. CLA-1/SRBI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferatoractivated receptors. Circulation 2000; 101: 2411–7. [Google Scholar]
  7. Chinetti G, Lestavel S, Bocher V, et al. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 2001; 7: 53–8. [Google Scholar]
  8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans affairs highdensity lipoprotein cholesterol intervention trial study group. N Engl J Med 1999; 341: 410–8. [Google Scholar]
  9. DAIS-group. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study. Lancet 2001; 357: 905–10. [Google Scholar]
  10. BIP group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102: 21–7. [Google Scholar]
  11. Tenkanen L, Manttari M, Manninen V. Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study. Circulation 1995; 92: 1779–85. [Google Scholar]
  12. Barroso I, Gurnell M, Crowley VE, et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880–3. [Google Scholar]
  13. Arner P. The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones. Trends Endocrinol Metab 2003; 14: 137–45. [Google Scholar]
  14. Guan HP, Li Y, Jensen MV, Newgard CB, Steppan CM, Lazar MA. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002; 8: 1122–8. [Google Scholar]
  15. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106: 1305–7. [Google Scholar]
  16. Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol 2003; 23: 1042–7. [Google Scholar]
  17. Holst D, Grimaldi PA. New factors in the regulation of adipose differentiation and metabolism. Curr Opin Lipidol 2002; 13: 241–5. [Google Scholar]
  18. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376–80. [Google Scholar]
  19. Camp HS, Li O, Wise SC, et al. Differential activation of peroxisome proliferatoractivated receptor- gamma by troglitazone and rosiglitazone. Diabetes 2000; 49: 539–47. [Google Scholar]
  20. Olefsky JM. Treatment of insulin resistance with peroxisome proliferatoractivated receptor gamma agonists. J Clin Invest 2000; 106: 467–72. [Google Scholar]
  21. Mukherjee R, Hoener PA, Jow L, et al. A selective peroxisome proliferatoractivated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 2000; 14: 1425–33. [Google Scholar]
  22. Oberfield JL, Collins JL, Holmes CP, et al. A peroxisome proliferatoractivated receptor gamma ligand inhibits adipocyte differentiation. Proc Natl Acad Sci USA 1999; 96: 6102–6. [Google Scholar]
  23. Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferatoractivated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 2002; 16: 2628–44. [Google Scholar]
  24. Lohray BB, Lohray VB, Bajji AC, et al. (-)3-[4-[2- (Phenoxazin-10- yl)ethoxy]phenyl]-2- ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 2001; 44: 2675–8. [Google Scholar]
  25. Etgen GJ, Oldham BA, Johnson WT, et al. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models. Diabetes 2002; 51: 1083–7. [Google Scholar]
  26. Vikramadithyan RK, Hiriyan J, Gershome C, Rajagopalan R, Chahrabarti R. Biochemical effects of the dual PPARalpha and gamma agonist ragaglitazar on glucose and lipid metabolism. San Francisco: American Diabetes Association, 2002: abstract 584–P. [Google Scholar]
  27. Ide T, Nakazawa T, Mochizuki T, Murakami K. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 2000; 49: 521–5. [Google Scholar]
  28. Shibata T, Takeuchi S, Yokota S, Kakimoto K, Yonemori F, Wakitani K. Effects of peroxisome proliferator-activated receptor-alpha and - gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats. Br J Pharmacol 2000; 130: 495–504. [Google Scholar]
  29. Ye JM, Iglesias MA, Watson DG, et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 2003; 284: E531–40. [Google Scholar]
  30. Murakami K, Tobe K, Ide T, et al. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPARalpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats. Diabetes 1998; 47: 1841–7. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.